Hepatitis B Needlestick PEP Advisor

◆ Evidence-Based Pearls HBV Transmission Risk After Needlestick

⚠ HBV is the highest-risk bloodborne pathogen in needlestick injuries. The seroconversion risk from a single percutaneous exposure is 6-30 times higher than HIV.

Pathogen	Risk per Percutaneous Exposure
HBV (HBsAg+ / HBeAg+ source)	22-31% (clinical hepatitis); 37-62% (serological evidence)
HBV (HBsAg+ / HBeAg- source)	1-6% (clinical); 23-37% (serological)
HCV	~1.8% (range 0-7%)
HIV	~0.3%

Body fluids considered infectious: Blood (highest titre), cerebrospinal fluid, synovial, pleural, peritoneal, pericardial, amniotic fluids, semen, vaginal secretions.
NOT efficiently infectious: Saliva (unless blood-tinged), tears, sweat, urine, faeces, breast milk (low titre, not occupational risk).
Hollow-bore needles carry higher risk than solid needles or superficial scratches (larger volume of blood transferred).

The Master PEP Decision Table

💡 Key Principle: The decision hinges on two axes: (1) the vaccination and antibody status of the exposed person, and (2) the HBsAg status of the source patient.

Exposed Person Status	Source HBsAg+	Source HBsAg-	Source Unknown
Unvaccinated	HBIG ×1 + Vaccine series	Vaccine series	Vaccine series (consider HBIG if high-risk source)
Vaccinated, responder (anti-HBs ≥10)	No treatment	No treatment	No treatment
Vaccinated, response unknown	Test anti-HBs urgently. If <10: HBIG ×1 + revaccinate	Test anti-HBs. If <10: revaccinate	Test anti-HBs urgently. If <10: HBIG ×1 + revaccinate
Non-responder (1 series)	HBIG ×1 + 2nd vaccine series	2nd vaccine series	HBIG ×1 + 2nd vaccine series
Non-responder (2 series)	HBIG ×2 (0 & 1 month)	No treatment	HBIG ×2 (0 & 1 month)

Hepatitis B Immunoglobulin (HBIG)

Parameter	Detail
Product	HBIG is a sterile solution of human immunoglobulin G (IgG) with high titre of anti-HBs antibodies. Prepared from plasma of donors with high anti-HBs levels.
Dose	0.06 ml/kg body weight, IM (gluteal or deltoid).
Timing	Within 24 hours of exposure (preferably within 12 hours). Efficacy declines sharply. Unlikely to be effective beyond 7 days for percutaneous exposures.
Administration with vaccine	Can be given simultaneously with HepB vaccine but at different anatomical sites using separate syringes.
Safety	Well tolerated. Safe in pregnancy and lactation. No evidence of HBV, HIV, or HCV transmission from HBIG.

Hepatitis B Vaccine in the PEP Setting

Standard adult dose: 20 µg (1.0 ml) IM in deltoid. CKD/dialysis patients: 40 µg.
Primary series: 3 doses at 0, 1, and 6 months. Do NOT restart the series if doses are delayed; continue from where interrupted.
Postvaccination testing: Check anti-HBs 1-2 months after completing the series. Target: ≥10 mIU/ml.
Non-responders: Repeat the full 3-dose series. If anti-HBs still <10 after 2 complete series, the person is a "true non-responder" and must rely on HBIG for post-exposure protection.
Booster doses: NOT routinely recommended for immunocompetent responders. Consider for CKD/dialysis patients if anti-HBs falls below 10 mIU/ml on annual testing.

Immediate First Aid After Exposure

⚠ Time is critical. Initiate first aid immediately. Do NOT delay to wait for source patient results. PEP should ideally be initiated within 24 hours.

Exposure	Action
Needlestick / Sharp	Allow wound to bleed freely briefly. Wash thoroughly with soap and running water for 15 minutes. Apply antiseptic (Povidone Iodine or Chlorhexidine). Do NOT squeeze or "milk" the wound.
Mucosal splash (eyes)	Irrigate eyes with clean water or normal saline for at least 15 minutes. Remove contact lenses first.
Mucosal splash (mouth/nose)	Rinse thoroughly with water. Spit out. Do NOT swallow.
Non-intact skin	Wash area with soap and water for 15 minutes.

✗ Do NOT use bleach, alcohol, or disinfectants directly on the wound (tissue damage).
✗ Do NOT squeeze or "milk" the puncture site (may increase venom/pathogen absorption).
✓ Report the exposure to the designated authority (Infection Control Officer / Occupational Health) immediately.
✓ Document: time, mechanism, body fluid involved, source patient details, first aid given.

Simultaneous Evaluation Checklist at Presentation

💡 Do BOTH simultaneously without delay:

Exposed Person	Source Patient
Verify vaccination records (written, dated documentation only)	Test HBsAg (stat / rapid test if available)
Test anti-HBs level (if vaccinated but response unknown)	Test anti-HCV antibodies
Baseline HBsAg, anti-HBc, anti-HBs	Test HIV (with consent per local protocol)
Baseline anti-HCV, HIV (with consent)	Document known comorbidities

Indian Context & HCW Vaccination

⚠ Indian Reality: HBV carrier rate in India is 3-4%. Hepatitis B vaccination among healthcare workers, while recommended, is not universally implemented. Many HCWs in government hospitals remain unvaccinated or have never had postvaccination testing.

NIS Status: Td replaced TT in 2019, but Hepatitis B vaccination for HCWs is recommended (not mandated under law in all states). IAP and API both strongly recommend it.
HBIG availability: HBIG is available in India (brands: Hepatect, HepaBig, HepaRab) but is expensive (~₹4,000-8,000 per dose) and may not be stocked in all PHCs/CHCs.
Alternative when HBIG unavailable: If HBIG is unavailable, administer the HepB vaccine immediately and refer for HBIG within 24 hours. Some experts recommend high-dose (40 µg) vaccine if HBIG is not accessible, though this is NOT a substitute.
OSHA equivalent: India's Bio-Medical Waste Management Rules (2016) and the Occupational Safety and Health directives for hospitals provide the legal framework, though enforcement varies.

Managing the Non-Responder

Status	Action
Non-responder after 1 series	Give a second complete 3-dose series (0, 1, 6 months). Check anti-HBs 1-2 months after dose 6. ~30-50% respond to a second series.
Non-responder after 2 series	Labelled a "true non-responder." Further vaccination is futile. Must rely on HBIG (2 doses, 1 month apart) for each high-risk exposure. Counsel about transmission precautions.
Alternatives being studied	Double-dose (40 µg) vaccination, intradermal route, adjuvanted vaccines (HepB-CpG). Not yet standard of care.

Don't Forget: HCV & HIV Co-Assessment

⚠ Every needlestick exposure warrants simultaneous evaluation for HBV, HCV, and HIV. This tool addresses the HBV component. Always assess and manage the other two in parallel.

Pathogen	PEP Available?	Key Action
HBV	YES (HBIG + Vaccine)	This tool. HBIG within 24 hours.
HIV	YES (ART-based PEP)	Initiate within 72 hours (ideally 2 hours). 28-day course of TDF/FTC + Dolutegravir (or Raltegravir).
HCV	NO	No approved PEP. Baseline anti-HCV and follow-up at 6 months. If seroconversion: treat with DAAs (cure rate >95%).

ER Traps & Common Errors

✗ Trap: Accepting verbal claims of vaccination without written documentation. Self-reported history is unreliable. If no written record: treat as unvaccinated.
✗ Trap: Waiting for source patient results before initiating PEP. Start HBIG within 24 hours. You can discontinue if source tests HBsAg-negative.
✗ Trap: Forgetting to check anti-HBs in vaccinated HCWs with unknown response. This is the single most common gap.
✗ Trap: Administering HBIG and vaccine in the same syringe or at the same site. Always use separate syringes at different anatomical sites.
✗ Trap: Not completing the vaccine series after the exposure dose. The initial vaccine dose is NOT sufficient; the patient needs the full 0, 1, 6 month series.
✓ Pearl: A known responder (anti-HBs ≥10 at any time in the past) is protected for life against clinical disease, even if anti-HBs subsequently wanes to undetectable levels. Immunological memory persists.
✓ Pearl: Pregnancy is NOT a contraindication to HepB vaccine or HBIG. Both are safe and must not be withheld.